KR20250099050A - 표적 세포의 세포 표면에 존재하는 인간 srrm2에 결합하는 항체를 포함하는 조성물 - Google Patents

표적 세포의 세포 표면에 존재하는 인간 srrm2에 결합하는 항체를 포함하는 조성물 Download PDF

Info

Publication number
KR20250099050A
KR20250099050A KR1020247034002A KR20247034002A KR20250099050A KR 20250099050 A KR20250099050 A KR 20250099050A KR 1020247034002 A KR1020247034002 A KR 1020247034002A KR 20247034002 A KR20247034002 A KR 20247034002A KR 20250099050 A KR20250099050 A KR 20250099050A
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
antibody
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034002A
Other languages
English (en)
Korean (ko)
Inventor
라인하르트 자이들러
카트린 게르트너
Original Assignee
헬름홀츠 젠트룸 뮌헨-도이체스 포르슝스젠트룸 퓌르 게준드하이트 운트 움벨트 게엠베하
헬름홀츠 젠트룸 뮌헨-도이체스 포르슝스젠트룸 퓌르 게준드하이트 운트 움벨트 게엠베하
크리니쿰 데어 루트비히-막시밀리안-우니베르시태트 뮌헨 (엘엠유 크리니쿰) 안슈탈트 데스 외펜틀리헨 레흐츠
엑심미움 바이오테크놀로지스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헬름홀츠 젠트룸 뮌헨-도이체스 포르슝스젠트룸 퓌르 게준드하이트 운트 움벨트 게엠베하, 헬름홀츠 젠트룸 뮌헨-도이체스 포르슝스젠트룸 퓌르 게준드하이트 운트 움벨트 게엠베하, 크리니쿰 데어 루트비히-막시밀리안-우니베르시태트 뮌헨 (엘엠유 크리니쿰) 안슈탈트 데스 외펜틀리헨 레흐츠, 엑심미움 바이오테크놀로지스 게엠베하 filed Critical 헬름홀츠 젠트룸 뮌헨-도이체스 포르슝스젠트룸 퓌르 게준드하이트 운트 움벨트 게엠베하
Publication of KR20250099050A publication Critical patent/KR20250099050A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020247034002A 2022-03-14 2023-03-14 표적 세포의 세포 표면에 존재하는 인간 srrm2에 결합하는 항체를 포함하는 조성물 Pending KR20250099050A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22161839.0 2022-03-14
EP22161839 2022-03-14
PCT/EP2023/056397 WO2023174897A1 (en) 2022-03-14 2023-03-14 Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell

Publications (1)

Publication Number Publication Date
KR20250099050A true KR20250099050A (ko) 2025-07-01

Family

ID=80738871

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034002A Pending KR20250099050A (ko) 2022-03-14 2023-03-14 표적 세포의 세포 표면에 존재하는 인간 srrm2에 결합하는 항체를 포함하는 조성물

Country Status (6)

Country Link
EP (1) EP4493587A1 (https=)
JP (1) JP2025510642A (https=)
KR (1) KR20250099050A (https=)
CN (1) CN119156400A (https=)
CA (1) CA3245743A1 (https=)
WO (1) WO2023174897A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025255706A1 (en) * 2024-06-11 2025-12-18 Zeno Therapeutics Pte. Ltd. Diagnosis and treatment of aml
WO2025054760A1 (en) * 2023-09-11 2025-03-20 Zeno Therapeutics (Shenzhen) Co. Ltd. Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell
WO2025056603A1 (en) * 2023-09-11 2025-03-20 Eximmium Biotechnologies Gmbh Srrm2 binders for treating and diagnosing blood cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
1. Hashimoto-Gotoh, T. et al. (1995) Gene 152, 271-275.
2. Kramer, W. et al. (1984) Nucleic Acids Res. 12, 9441-9456.
3. Kunkel, TA (1985) Proc Natl Acad Sci USA. 82, 488-492.
4. Kunkel (1988) Methods Enzymol. 85, 2763-2766.
5. Mark, D. F. et al., Proc. Natl. Acad. Sci. USA (1984) 81, 5662-5666, Zoller, M. J. and Smith, M., Nucleic Acids Research (1982) 10, 6487-6500.
6. Wang, A. et al., Science 224, 1431-1433, Dalbadie-McFarland, G. et al., Proc. Natl. Acad. Sci. USA (1982) 79, 6409-641.
7. Weidle, U. H., Maisel, D., Klostermann, S., Schiller, C., and Weiss, E. H. (2011). Intracellular proteins displayed on the surface of tumor cells as targets for therapeutic intervention with antibody-related agents. Cancer Genomics Proteomics 8, 49-63.
8. Zoller, MJ, and Smith, M. (1983) Methods Enzymol. 100, 468-500.

Also Published As

Publication number Publication date
CA3245743A1 (en) 2023-09-21
WO2023174897A1 (en) 2023-09-21
EP4493587A1 (en) 2025-01-22
JP2025510642A (ja) 2025-04-15
CN119156400A (zh) 2024-12-17

Similar Documents

Publication Publication Date Title
EP4640710A1 (en) Monoclonal antibody specifically binding to claudin-18.2 and use thereof
CN101631802B (zh) 在体内具有抗肿瘤活性的抗人Dlk-1抗体
KR20250099050A (ko) 표적 세포의 세포 표면에 존재하는 인간 srrm2에 결합하는 항체를 포함하는 조성물
JP2022025071A (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
EP2275537B1 (en) Anti-human dlk-1 antibody having anti-tumor activity in vivo
JP7024072B2 (ja) 抗ｃｄ３抗体およびそれを含む癌処置用医薬組成物
TW202204416A (zh) 抗Ｃｌａｕｄｉｎ１８．２抗體以及其用途
US20180002439A1 (en) Anti-mesothelin antibodies and uses thereof
JP4852046B2 (ja) 癌の治療及び検出に用いる結合分子
KR102149565B1 (ko) in vivo 에서 항종양 활성을 갖는 항인간 Dlk-1 항체
US20260116991A1 (en) Monoclonal antibody for specifically recognizing glypican-3, and application thereof
TW202402805A (zh) 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法
US7396915B2 (en) Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
US9273140B2 (en) Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D
US20240050475A1 (en) Composition comprising an antibody which binds to human prdx4 present on the cell surface of a target cell
WO2025054760A1 (en) Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell
WO2025255706A1 (en) Diagnosis and treatment of aml
WO2025125557A1 (en) Composition comprising an antibody which binds to human igf2bp1 present on the cell surface of a target cell
CN116981688A (zh) 包含结合存在于靶细胞的细胞表面上的人prdx4的抗体的组合物
CN100543135C (zh) 单克隆抗体及编码其的基因、药物组合物和诊断试剂
AU2024340551A1 (en) Srrm2 binders for treating and diagnosing blood cancer
WO2023190465A1 (ja) 抗ヒトｓｅｍａ７ａ抗体
CN119985271A (zh) 表面srrm2作为aml的预后生物标志物和免疫疗法的分子靶标
JP2005040126A (ja) モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241011

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application